title: Inhibition of 20-HETE attenuates diabetes-induced decreases in retinal hemodynamics.
abstract: The mechanisms of early diabetes-induced decreases in retinal blood flow have yet to be fully determined. The aim of this study was to explore the hypothesis that 20-hydroxyeicosatetraenoic acid (20-HETE) plays a role in the early decrease of retinal hemodynamics in diabetic mice. 20-HETE has been implicated previously in the diabetes-enhanced vasoconstriction of mesenteric and renal vessels; however, its role in the diabetic retinal microcirculation has not been investigated. Diabetes was induced by multiple low-dose injections of streptozotocin (STZ; 50 mg/kg for 5 consecutive days), then ∼2 weeks later the mice were administered daily intraperitoneal injections with or without the 20-HETE inhibitor HET0016 (2.5 mg/kg/day) for the following 2 weeks. Non-diabetic age-matched mice were included as controls. Intravital microscopy was used to obtain measurements of retinal vascular diameters and red blood cell (RBC) velocities for the feed arterioles and draining venules extending out of and into the optic disk. From these values, wall shear rates and blood flow rates were calculated. Diabetes induced approximately 30-40% decreases in RBC velocity, wall shear rate, and blood flow rate. These decreases were attenuated to 5-10% in the mice given HET0016. In summary, the 20-HETE inhibitor HET0016 is able to attenuate the retinal hemodynamic changes induced by diabetes.
authors.affiliation: Department of Molecular & Cellular Physiology, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA.
authors.forename: Zhongli
authors.initials: Z
authors.lastname: Wang
authors.forename: Amit Singh
authors.initials: AS
authors.lastname: Yadav
authors.forename: Wendy
authors.initials: W
authors.lastname: Leskova
authors.forename: Norman R
authors.initials: NR
authors.lastname: Harris
mesh_terms: D000578:Amidines / Q000494:pharmacology*; D000818:Animals; D001783:Blood Flow Velocity / Q000502:physiology; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology / Q000517:prevention & control*; D003930:Diabetic Retinopathy / Q000503:physiopathology / Q000517:prevention & control*; D004912:Erythrocytes / Q000502:physiology; D006893:Hydroxyeicosatetraenoic Acids / Q000037:antagonists & inhibitors*; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D012039:Regional Blood Flow / Q000502:physiology; D012171:Retinal Vessels / Q000187:drug effects* / Q000503:physiopathology
chemical_list: D000578:Amidines; C000708209:HET0016; D006893:Hydroxyeicosatetraenoic Acids; C055987:20-hydroxy-5,8,11,14-eicosatetraenoic acid